


## CYP2C19-genotype guided antiplatelet tx may be beneficial

November 3 2017



(HealthDay)—Patients with a CYP2C19 loss-of-function allele have



increased risk of major adverse cardiovascular events (MACE) with clopidogrel versus alternative antiplatelet therapy after percutaneous coronary intervention (PCI), according to a study published online Nov. 1 in *JACC: Cardiovascular Interventions*.

Larisa H. Cavallari, Pharm.D., from the University of Florida in Gainesville, and colleagues examined outcomes following clinical implementation of *CYP2C19* genotype-guided antiplatelet therapy after PCI. The authors compared MACE within 12 months of PCI for patients with a loss-of-function allele prescribed clopidogrel versus alternative therapy.

The researchers found that 31.5 percent of the 1,815 patients had a loss-of-function allele. Patients with a loss-of-function allele prescribed clopidogrel had a significantly higher risk for MACE versus those prescribed alternative therapy (23.4 versus 8.7 per 100 patient-years; adjusted hazard ratio, 2.26; 95 percent confidence interval, 1.18 to 4.32; P = 0.013). Among the 1,210 patients with an acute coronary syndrome at the time of PCI, the results were similar (adjusted hazard ratio, 2.87; 95 percent confidence interval, 1.35 to 6.09; P = 0.013). Patients without a loss-of-function allele and loss-of-function allele carriers prescribed alternative therapy had no difference in MACE (adjusted hazard ratio, 1.14; 95 percent confidence interval, 0.69 to 1.88; P = 0.6).

"A future randomized study of genotype-guided antiplatelet therapy may be of value," the authors write.

Two authors disclosed ties to the pharmaceutical industry.

More information: Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)



## Copyright © 2017 HealthDay. All rights reserved.

Citation: CYP2C19-genotype guided antiplatelet tx may be beneficial (2017, November 3) retrieved 9 April 2024 from

https://medicalxpress.com/news/2017-11-cyp2c19-genotype-antiplatelet-tx-beneficial.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.